Axial

Aquavit Files Additional IND for DTX-024, a New Botulinum Toxin With Microchannel Technology™ for Palmar Hyperhidrosis

Retrieved on: 
Saturday, March 18, 2023
Neurotoxin, BA, Drug development, Columbia University Vagelos College of Physicians and Surgeons, University, Hyperhidrosis, Allergan, MBA, Uniform Securities Agent State Law Exam, Doctor of Philosophy, Aquavit, Harvard Medical School, Dermatology, Investment, Patient, Physician, Ophthalmology, FINRA, Axial, Drug discovery, Knowledge, Health, FDA, IND, Clostridium botulinum, Neurology, University of Oxford, Pharmaceutical industry, Management, MD

NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.

Key Points: 
  • NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™.
  • Alongside Aquavit's biosimilar program for its botulinum toxin, this will be the first in the world, indicated for palmar hyperhidrosis, approved by FDA.
  • Aquavit has been investing in proprietary delivery technologies and related intellectual property for botulinum toxin.
  • This is a strategic move that puts them ahead of the curve in the fast-growing multi-billion-dollar botulinum toxin market.

Ocient Sees 171% Growth Demonstrating High Demand for Hyperscale Data Analytics, ELT, and Machine Learning to Power Data-Intensive Innovation and Digital Transformation

Retrieved on: 
Wednesday, February 22, 2023
Apps, Applications, Technology, Mobile, Wireless, Security, Software, Networks, Internet, Data Management, Artificial Intelligence, Momentum, Cloud, Marketing, Basis Technology, Carbon, ETL, Tableau, Forrester Research, IBM, DB2 SQL return codes, ESG, BI, Organization, Cloud Data Management Interface, Chicago Innovation Awards, Partnership, AWS, Engineering, ROI, Database, MVP, Automation, Dagboek van een Oude Dwaas, AI, Growth, GA, Price–performance ratio, IBM Db2, Machine learning, IIS Metabase, Retail, Renewable energy, Video game, Online shopping, Cryptocurrency, Sales, Axial, Chris Gladwin (engineer), Amdocs, Carahsoft, Subset

Ocient also continued its commitment to digital sustainability and carbon neutrality with carbon offsets, green data centers and employee engagement programs.

Key Points: 
  • Ocient also continued its commitment to digital sustainability and carbon neutrality with carbon offsets, green data centers and employee engagement programs.
  • Ocient achieves 171% year-over-year growth, surpassing the company’s fiscal year projections
    After developing its core data engine for six years, Ocient announced the general availability of its core product, the Ocient Hyperscale Data Warehouse at version 19.
  • Following the initial GA release of the Ocient Hyperscale Data Warehouse version 19 , Ocient released two additional versions of its flagship product.
  • “We’re thrilled to see rapid adoption of our hyperscale data analytics capabilities across a variety of industries and use cases,” said Gladwin.

Peakstone ranked #1 by Axial

Retrieved on: 
Tuesday, January 31, 2023
Axial, Acquisition, News, Retail

CHICAGO , Jan. 31, 2023 /PRNewswire/ -- We are pleased to announce that Axial ranked Peakstone the #1 lower middle market U.S. investment bank of 2022.

Key Points: 
  • CHICAGO , Jan. 31, 2023 /PRNewswire/ -- We are pleased to announce that Axial ranked Peakstone the #1 lower middle market U.S. investment bank of 2022.
  • Peakstone has been ranked #1 three times by Axial in their 2021 and 2022 quarterly and annual ranking reports.
  • Axial's league tables take into account three main characteristics: client quality, buy-side targeting, and process effectiveness.
  • Our team is comprised of senior investment banking professionals who have decades of experience and have executed hundreds of transactions totaling billions of dollars.

Axial Releases Its 2022 Lower Middle Market Investment Bank League Tables

Retrieved on: 
Wednesday, February 1, 2023
Small business, Food, Hospitality and Services Union, Business development, Health, Transport, IPO, Axial

NEW YORK, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Axial, the online platform for American small business M&A, released its 2022 Annual Lower Middle Market Investment Banking League Tables.

Key Points: 
  • NEW YORK, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Axial, the online platform for American small business M&A, released its 2022 Annual Lower Middle Market Investment Banking League Tables.
  • The first of its kind in the small business M&A and lower middle market M&A ecosystem, Axial's league tables surface some of the most trusted and effective M&A professionals advising business owners on exit strategy and deal execution.
  • Top-of-funnel deal activity on Axial nonetheless grew in 2022, with over 9,900 business owners confidentially exploring an exit via Axial during the year," says Peter Lehrman, founder and CEO of Axial.
  • We're looking forward to continuing to support the lower middle market's business owners and dealmakers in 2023."

$375+ Million Bone Densitometer (DEXA, Peripheral) Markets: Increasing Prevalence of Osteoporosis to Drive the Market for Bone Densitometers - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Medical Devices, Health, Cone beam computed tomography, Woman, DEXA, USD, OSI Systems, Rheumatoid arthritis, Osteopenia, Incidence, CKD, Growth, Axial, GE Healthcare, Osteoporosis, Hospital, Cystic fibrosis, Risk, Medical imaging, Dietary supplement, Healthcare

The global bone densitometer market is projected to reach USD 378 million by 2027 from USD 299 million in 2022, at a CAGR of 4.7% during the forecast period.

Key Points: 
  • The global bone densitometer market is projected to reach USD 378 million by 2027 from USD 299 million in 2022, at a CAGR of 4.7% during the forecast period.
  • The axial bone densitometry segment is expected to account for the largest share of the bone densitometer market.
  • The osteoporosis & osteopenia diagnosis segment is expected to account for the largest share of the bone densitometer market.
  • The osteoporosis & osteopenia diagnosis segment accounted for the largest share of the global bone densitometer market in 2021.

Axial's 2022 Lower Middle Market Pursuits Report Highlights the Market's Stability in the Face of Volatility

Retrieved on: 
Thursday, November 17, 2022
Marketing, Small business, LOI, Letter, Sales, Axial

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Axial, the online M&A platform for small business acquisitions, has released its Q3 2022 Lower Middle Market Pursuits Report.

Key Points: 
  • NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Axial, the online M&A platform for small business acquisitions, has released its Q3 2022 Lower Middle Market Pursuits Report.
  • Lower middle market buyers grew more serious in the third quarter, with LOI activity beginning to reflect the top of funnel activity witnessed in the first half of 2022.
  • "The first half of 2022 was characterized by lots of top-of-funnel conversation and connection between buyer and seller, but much more limited LOI and closed deal activity.
  • The company's pioneering deal sourcing and deal marketing platforms are trusted by professional acquirers, top lower middle market M&A advisors, and transaction-ready business owners.

Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022

Retrieved on: 
Tuesday, November 1, 2022
Autism, GLOBE, Axial, Bacteria, W. Stewart Campbell, Learning, Therapy, Irritability, Drug development, Central nervous system, Pharmaceutical industry

The event will bring together 300+ leaders from the microbiome community for three days of learning, networking and forging successful partnerships at a pivotal time for microbial drug development.

Key Points: 
  • The event will bring together 300+ leaders from the microbiome community for three days of learning, networking and forging successful partnerships at a pivotal time for microbial drug development.
  • Axial Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and conditions.
  • The company is a scientific leader in the biological role of the microbiome-gut-brain axis and its influence on the central nervous system.
  • Axials lead product candidate is AB-2004, a molecular therapeutic in Phase 2b clinical trials for the treatment of irritability in children with autism.

eMerge M&A Ranked #1 Lower Middle Market Investment Bank by Axial

Retrieved on: 
Tuesday, November 1, 2022
Enterprise value, LOI, Standings, GLOBE, NDAS, Criterion, Intention, Lois, Gentlemen's agreement, Emerge, TEV, Financial adviser, Risk management, Axial

eMerge M&A has worked with, and sold, hundreds of private companies and completed over $5 billion in transactions.

Key Points: 
  • eMerge M&A has worked with, and sold, hundreds of private companies and completed over $5 billion in transactions.
  • We get to know the owners' companies as well as they know their own companies to be most effective in the market.
  • Axial is the trusted deal platform serving the lower middle market ($5-$250M Total Enterprise Value (TEV)).
  • Closed Deals: How many deals have the advisor closed where they involved one or more Axial buyers in the process.

Former YASA CEO Chris Harris to Lead Electric Aerospace Powertrain Company Evolito as It Accelerates the Commercialisation of Electric Flight

Retrieved on: 
Tuesday, November 1, 2022
Technology, EV, Electric Vehicles, Automotive, General Automotive, Air, Transport, Other Automotive, Software, Hardware, Data Management, OEM, Electronics, Ferrari, CEO, Acquisition, Lead, OSE, Axial, Technology, Travel, Contract, Aviation, EV, Urban air mobility, Original equipment manufacturer, Multimedia, Torque, IP, Mercedes-Benz, Partnership, Solution, Management, Renewable energy, Electric motor, EVTOL

Evolito Limited , a privately-owned company developing and manufacturing electric motors and powertrains for aerospace applications, has today announced former YASA CEO, Dr. Chris Harris, is joining the company as CEO.

Key Points: 
  • Evolito Limited , a privately-owned company developing and manufacturing electric motors and powertrains for aerospace applications, has today announced former YASA CEO, Dr. Chris Harris, is joining the company as CEO.
  • Following 15 years experience building and leading high-tech, high-growth businesses in the UK, Europe and US, Dr. Chris Harris joined YASA in 2012.
  • Under Chris Harris leadership, Evolitos revolutionary electric motors and powertrains will enable electric flight to become a commercial reality in the near future.
  • Dr. Chris Harris, Evolito co-founder and CEO said, Electric flight requires ultra high-power density, super low-weight electric powertrains.

Axial Releases the Top 25 Lower Middle Market Investment Banks for Q3 2022

Retrieved on: 
Thursday, October 20, 2022
Marketing, Hospitality, Health care, Technology, Employment, Food, Food, Hospitality and Services Union, CEO, Transport, GLOBE, EBITDA, Financial services, Recession, Final good, Corporate services, Renewable energy, Energy, Axial, Q3

NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axial, the online M&A platform for buyers, advisors, and sellers of small and medium-sized businesses, has released its Q3 2022 Lower Middle Market Investment Banking League Tables.

Key Points: 
  • NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Axial, the online M&A platform for buyers, advisors, and sellers of small and medium-sized businesses, has released its Q3 2022 Lower Middle Market Investment Banking League Tables.
  • And nowhere is this clearer than in the lower middle market, which continues to see robust deal flow despite slightly relaxed growth in Q3.
  • Congratulations to Q3's Top 25 lower middle market investment banks for their strong results during this period."
  • Investment banks took more than 680 deals to market via Axial in Q3, representing a 19.6% increase in year-over-year deal flow.